Inhibition of nuclear factor-kappa B differentially affects thyroid cancer cell growth, apoptosis, and invasion
© Bauerle et al; licensee BioMed Central Ltd. 2010
Received: 8 March 2010
Accepted: 21 May 2010
Published: 21 May 2010
Nuclear factor-κB (NF-κB) is constitutively activated in many cancers and plays a key role in promoting cell proliferation, survival, and invasion. Our understanding of NF-κB signaling in thyroid cancer, however, is limited. In this study, we have investigated the role of NF-κB signaling in thyroid cancer cell proliferation, invasion, and apoptosis using selective genetic inhibition of NF-κB in advanced thyroid cancer cell lines.
Three pharmacologic inhibitors of NF-κB differentially inhibited growth in a panel of advanced thyroid cancer cell lines, suggesting that these NF-κB inhibitors may have off-target effects. We therefore used a selective genetic approach to inhibit NF-κB signaling by overexpression of a dominant-negative IκBα (mIκBα). These studies revealed decreased cell growth in only one of five thyroid cancer cell lines (8505C), which occurred through a block in the S-G2/M transition. Resistance to TNFα-induced apoptosis was observed in all cell lines, likely through an NF-κB-dependent mechanism. Inhibition of NF-κB by mIκBα sensitized a subset of cell lines to TNFα-induced apoptosis. Sensitive cell lines displayed sustained activation of the stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK) pathway, defining a potential mechanism of response. Finally, NF-κB inhibition by mIκBα expression differentially reduced thyroid cancer cell invasion in these thyroid cancer cell lines. Sensitive cell lines demonstrated approximately a two-fold decrease in invasion, which was associated with differential expression of MMP-13. MMP-9 was reduced by mIκBα expression in all cell lines tested.
These data indicate that selective inhibition of NF-κB represents an attractive therapeutic target for the treatment of advanced thyroid. However, it is apparent that global regulation of thyroid cancer cell growth and invasion is not achieved by NF-κB signaling alone. Instead, our findings suggest that other important molecular processes play a critical role in defining the extent of NF-κB function within cancer cells.
Thyroid cancer is the most common endocrine malignancy . Fortunately, a majority of patients are managed successfully with a combination of radioiodine and levothyroxine treatment following complete thyroidectomy. However, a subset of patients with advanced/dedifferentiated cancer have radioiodine-refractory disease with associated morbidity and mortality . Given the high frequency of activating mutations in the mitogen-activated protein kinase (MAPK) pathway achieved by rearrangements associated with the RET tyrosine kinase and activating point mutations in RAS and BRAF , therapies targeting this pathway have been an area of active investigation . Unfortunately, results from clinical studies regarding the overall efficacy of these therapies have been modest . Clearly, there remains a need for a better understanding of the molecular events involved in thyroid cancer initiation and progression to aid in the identification of novel therapeutic targets.
The nuclear factor-κB (NF-κB) family of transcription factors is comprised of RelA (p65), RelB, c-REL, NF-κB1/p50, and NF-κB2/p52, each of which is characterized by a Rel homology domain, which facilitates DNA-binding, homo- or heterodimerization of NF-κB family members, and interaction with inhibitory IκB proteins. A role for NF-κB in oncogenic progression has been described in a number of lymphoid malignancies and carcinomas, including thyroid, ovarian, breast, and hepatocellular carcinomas . Moreover, constitutive activation of NF-κB in tumors has been attributed to both excessive, chronic inflammation and activation by oncoproteins, as observed in hepatitis-induced hepatocellular carcinoma and melanoma, respectively [7, 8]. NF-κB activation has also been implicated in acquired resistance to chemotherapy and radiation [9, 10]. The end-product of NF-κB activation in cancer is believed to entail enhanced cell proliferation and invasion, as well as resistance to apoptosis induced by tumor surveillance mechanisms and various therapeutic modalities [10, 11].
While the two primary modes of NF-κB activation are similar in that they culminate in NF-κB-dependent gene regulation through nuclear translocation of NF-κB dimers, the pathways are distinguished by the differential requirement of the trimeric IκB kinase (IKK) complex, which is composed of two kinase subunits, IKKα and IKKβ, and a regulatory, scaffolding subunit IKKγ. The classical pathway of activation requires phosphorylation of IκB proteins by the trimeric IKK complex, resulting in proteasome-dependent degradation of the inhibitory proteins and nuclear translocation of the classical p50/p65 heterodimer. The alternative pathway involves cleavage of the NF-κB2 precursor protein into the functional p52 subunit, which may then complex with RelB. This pathway is dependent on phosphorylation of the NF-κB2 precursor by IKKα dimers .
To date, several studies have employed the use of pharmacologic inhibitors of NF-κB to establish a role for NF-κB in thyroid cancer cell growth and invasion [13–17]. However, these results should be interpreted with caution given the potential for off-target effects of many of these drugs. In this report, we used a selective genetic inhibitor of NF-κB (mIκBα) in a panel of authenticated thyroid cancer cell lines . We demonstrate that inhibition of NF-κB decreases thyroid cancer cell proliferation and invasion, while promoting TNFα-induced apoptosis. These findings are observed in only a subset of thyroid cancer cell lines and appear to be associated with distinct regulatory mechanisms.
Inhibition of Thyroid Cancer Cell Growth by Pharmacologic Inhibition of NF-κB
Pharmacologic inhibitors of NF-κB have been widely used to investigate the functional consequences of constitutive NF-κB activation in cancer. Many of these inhibitors prevent phosphorylation and degradation of IκBα by blocking IKK complex activity . We initially tested three NF-κB inhibitors, Bay 11-7082 (1 μM), IKK Inhibitor VII (1 μM), and CDDO-Me (0.25 μM), to investigate the role of NF-κB in thyroid cancer cell growth. The concentrations used in these experiments were based on studies using these compounds to document NF-κB-dependent effects on cell growth [20–22]. Each compound demonstrated inhibition of IKKβ activity by blocking TNFα-induced nuclear localization of p65 in a dose-dependent manner (data not shown).
Inhibition of NF-κB by Adenoviral-mediated Overexpression of mIκBα
The five thyroid cancer cell lines demonstrated different basal levels of NF-κB transcriptional activity as determined by an NF-κB-responsive luciferase reporter, with the BCPAP and 8505C cell lines exhibiting the highest levels of NF-κB activity (Figure 2B). Basal NF-κB activity did not correlate with tumor type (ATC vs. PTC). Figure 2C shows that NF-κB transcriptional activity could be inhibited by greater than 90% in each of the five cell lines. The degree of inhibition at a given MOI correlated with mIκBα protein expression in each of the cell lines. Importantly, transduction of cells with Ad-GFP at the same MOI had no effect on NF-κB transcriptional activity (data not shown). These results demonstrate effective inhibition of constitutive NF-κB activity in our panel of 5 thyroid cancer cell lines.
The Role of NF-κB in Thyroid Cancer Cell Growth
The Role of NF-κB in Resistance to TNFα-induced Apoptosis
The Role of NF-κB in Thyroid Cancer Cell Invasion
In this report, we have used a selective genetic inhibitor of NF-κB signaling to determine the effects of this pathway on proliferation, apoptosis, and invasion in a panel of ATC and PTC thyroid cancer cell lines. Our data indicate that NF-κB does not have one common role in the regulation of proliferation, apoptosis, or invasion in advanced thyroid cancer and that sensitivity to NF-κB inhibition does not correlate with baseline levels of NF-κB transcriptional activity. Instead, we have demonstrated that some cancer cells depend on NF-κB signaling for proliferation (8505C), while others require it for invasion and resistance to TNFα-induced apoptosis (TPC1, SW1736). Furthermore, some cell lines are not dependent on NF-κB signaling for these basic cancer properties (BCPAP, C643).
The hallmarks of cancer include self-sufficiency in growth signals, resistance to anti-growth signals, evasion of apoptosis, unlimited replication potential, sustained angiogenesis, and acquisition of metastatic/invasive potential . Activation of NF-κB signaling in cancer is a critical mediator in the majority, if not all, of these processes . This theory has led to numerous studies aimed at identifying a link between NF-κB signaling and thyroid cancer growth and progression. Using the NF-κB inhibitor DHMEQ, Yamashita and colleagues showed decreased tumor growth, cancer cell invasion, increased apoptosis, as well as TNFα- and taxane-induced apoptosis in a single ATC cell line [13, 14]. Liu and Xing demonstrated synergistic inhibition of cell proliferation in a panel of thyroid cancer cell lines when combining a MEK1/2 inhibitor with PS1145, an IKK complex inhibitor . Another study by Zhu and colleagues showed that a small molecule triptolide inhibited angiogenesis, invasion, and proliferation in a single ATC cell line and further suggested that this was associated with inhibition of NF-κB transcriptional activity . The primary genetic study linking NF-κB to thyroid cancer was performed by Pacifico and colleagues via stable overexpression of mIκBα in the FRO ATC cell line. In doing so, they showed that NF-κB promotes in vivo tumor formation, growth in soft-agar, and resistance to chemotherapy-induced apoptosis . Our studies have extended the use of a genetic model to identify a role for NF-κB signaling in a panel of authenticated thyroid cancer cell lines, and in doing so, we have advanced knowledge of the role of NF-κB in thyroid cancer proliferation, apoptosis, and invasion.
Previous studies in cancer models, including thyroid cancer, have cited a role for NF-κB in malignant cell proliferation by transcriptional regulation of cyclin D1, CDK2, cyclin E and c-Myc . Using a selective genetic model, however, we have shown that NF-κB regulates cancer cell proliferation in only one of five cell lines tested (Figure 3). Cell cycle arrest was induced in the 8505C ATC cell line by blocking the transition from S-phase to G2/M (Figure 4A), representing a novel mechanism for the regulation of thyroid cancer cell proliferation by NF-κB. While cyclin A is critical for progression through S-phase , protein levels were not affected by NF-κB inhibition (Figure 4B). Similarly, dephosphorylation of cdc2 at Tyr 15, which is predicted upon entry into G2/M , was observed (Figure 4B). However, protein levels of cyclin B1, which is necessary for the entry into and progression through G2-phase and mitosis , were decreased following NF-κB inhibition (Figure 4B). Interestingly, this finding was associated with increased levels of the cyclin-dependent kinase inhibitor, p21 (Figure 4B). Indeed, increased levels of p21 have been shown to mediate p53-induced cell cycle arrest in response to genotoxic stress by down-regulation of cyclin B1 expression . NF-κB signaling has also been shown to inhibit cell cycle arrest by decreasing p21 levels in osteoblasts  and normal epithelial cells in a manner dependent on the phosphatidylinositol-3-kinase (PI3K) pathway . Similar observations have been made in prostate cancer cells , thereby providing substantial evidence for a mechanism by which decreased NF-κB signaling in the 8505C cell line leads to decreased cyclin B1 expression in a p21-dependent manner.
The ability of NF-κB signaling to deregulate programmed cell death by apoptosis is a major mechanism by which NF-κB exerts its pro-tumorigenic functions. This effect is often achieved by transcriptional regulation of anti-apoptotic genes, including Bcl-2 family members [11, 13, 34]. Starenki and colleagues demonstrated that inhibition of NF-κB by DHMEQ in thyroid cancer cells induced spontaneous apoptosis through down-regulation of cIAP-1, cIAP-2, and XIAP . However, our studies indicate that genetic inhibition of NF-κB in a panel of thyroid cancer cell lines does not induce spontaneous apoptosis even under conditions of serum-starvation (Figure 3 and data not shown). Pacifico and colleagues obtained similar results when stably overexpressing mIκBα in the FRO ATC cell line .
NF-κB signaling is critical for blocking apoptosis following ligand binding by members of the tumor necrosis factor receptor (TNFR) superfamily. Members of this family induce activation of the extrinsic apoptosis pathway by a cytoplasmic death domain. These receptors include the classical receptor TNFR1, which binds the inflammatory cytokine TNFα, as well as Fas, TNF-related apoptosis-inducing ligand (TRAIL)-receptor 1, and TRAIL-R2 [35, 36]. Pro-apoptotic effects of TNFR1 activation by TNFα are two-fold. First, receptor activation induces formation of complex II, which ultimately triggers mitochondrial release of cytochrome c, and second, activation of the JNK/SAPK pathway results in downstream release of Smac/Diablo into the cytosol to activate caspase 8. However, under conditions in which NF-κB signaling is intact, the pro-apoptotic functions of TNFR1 activation are often masked due, in large part, to the survival functions imparted by NF-κB. Indeed, studies have shown that abrogation of NF-κB signaling can enhance TNFα-induced apoptosis . Our results demonstrate that inhibition of NF-κB signaling promotes TNFα-induced apoptosis in a subset of cell lines, and this finding is associated with a sustained activation of JNK in response to TNFα-treatment in the presence NF-κB inhibition in these cell lines (SW1736, TPC1) (Figure 6). Sustained activation of JNK was not observed in the resistant cell lines (BCPAP, C643). These data suggest a mechanism by which sensitization of thyroid cancer cell lines to the combinatorial effects of TNFα-treatment and NF-κB inhibition requires activation of the JNK pathway that may, in fact, be cell line and tumor specific. However, the exact mechanism by which differential activation of JNK remains unclear and may involve variable regulation of upstream signaling components. One study showed that breast cancer cells, which are typically resistant to TNFα-induced apoptosis, demonstrated enhanced apoptosis and prolonged activation of JNK when expressing mIκBα . The authors were able to block induction of apoptosis via treatment with an inhibitor of JNK activation. In our studies, however, treatment with the JNK inhibitor, SP600125, alone inhibited growth of our thyroid cancer cell lines (data not shown), likely due to off-target mechanisms associated with the compound, as described by Bain and colleagues . Another study reported a cell line-specific, differential activation of JNK following treatment of two oral squamous cell carcinoma (OSCC) lines with TRAIL, another ligand known to activate the TNFR superfamily . While this study did not involve inhibition of NF-κB, their basic findings were consistent with ours, in that a strong induction of JNK activation was necessary for OSCC sensitivity to TRAIL-induced apoptosis.
MMPs belong to a family of endopeptidases, which are classified based on their specificity for particular extracellular matrix substrates, and are believed to play a critical role in the acquisition of metastatic potential by cancer cells by promoting migratory/invasive potential. MMP regulation is governed by numerous oncogenic processes, including constitutive activation of NF-κB [40, 41]. In the current study, we have demonstrated differential regulation of invasion by NF-κB and evaluated the expression levels of MMP-2, -9, and -13. These MMPs are significant in that they are regulated by NF-κB (MMP-9) and expressed ubiquitously in thyroid cancer cell lines (MMP-13) [41, 42]. Also, expression of both MMP-2 and MMP-9 is increased in neoplastic thyroid cell lines when compared to normal thyroid cell lines [41, 42]. Only MMP-9 displayed significantly decreased transcript levels in response to NF-κB inhibition (Figure 8C). This finding is important, however, given the correlation with MMP-9 expression and poor prognosis in breast and prostate cancer. No significant regulation of MMP-2 or MMP-13 was observed. Interestingly, MMP-13 transcript levels at baseline were at least two-fold higher in the resistant cell lines (BCPAP, C643) when compared to transcript levels in sensitive cell lines (SW1736, TPC1) (Figure 7; Figure 8B). Further studies will be required to determine the precise mechanisms by which NF-κB regulates invasion in thyroid cancer cells. Nonetheless, the insights provided in this study clearly demonstrate a role for NF-κB in thyroid cancer cell invasion.
In conclusion, our results demonstrate an important and diverse role for NF-κB signaling in thyroid cancer. Interestingly, these effects are not observed across an entire panel of thyroid cancer cell lines, and they are not associated with a particular mutational status or histological tumor classification. Here, we show distinct roles for NF-κB signaling in the regulation of thyroid cancer cell proliferation, resistance to TNFα-induced apoptosis, and invasion. Decreased proliferation through blockade of the S-phase to G2/M transition is observed in response to NF-κB inhibition. Furthermore, NF-κB likely mediates cancer cell invasion, at least in part, by driving MMP-9 transcription. Finally, sensitivity to TNFα-induced apoptosis by inhibition of NF-κB is associated with sustained activation of the JNK pathway. Taken together, these results suggest that novel therapeutics targeting NF-κB may be of clinical utility in the treatment of advanced thyroid cancer, but this is not likely to be of global use in the treatment of all thyroid cancers. Downstream markers may identify which cell lines, and ultimately which patients, may respond to inhibitors of this important pathway.
The BCPAP, SW1736, 8505C, TPC1, and C643 thyroid cancer cell lines were maintained for 10-20 passages at 37°C and 5% CO2 in RPMI 1640 (Invitrogen) supplemented with 10% fetal bovine serum (FBS) (Hyclone). The BCPAP and 8505C cell lines were kindly provided by Dr. M. Santoro (Medical School, University "Federico II" of Naples, Naples, Italy). The SW1736 and C643 cell lines were kindly provided by Dr. K. Ain (University of Kentucky), with permission from Dr. N-E Heldin (University Hospital, S-751 85 Uppsala, Sweden). The TPC1 cell line was kindly provided by Dr. S. Jhiang (Ohio State University). Cell lines were routinely profiled by Short Tandem Repeat analysis and are consistent with our previously published profiles .
The NF-κB inhibitors, IKK Inhibitor VII (Calbiochem), Bay 11-7082 (Calbiochem), and CDDO-Me (kindly provided by Dr. M. Sporn, Dartmouth Medical School, Hanover, NH), were dissolved in DMSO at a final concentration of 10 mM.
Expression of mIκBα was achieved by adenoviral transduction. Ad-mIκBα and Ad-GFP were kindly provided by Dr. J. DeGregori (University of Colorado Denver, Anschutz Medical Campus, Aurora, CO) . For transduction, cells were trypsinized and resuspended in RPMI supplemented with 1% FBS, transduced in suspension for 1 hour with gentle agitation, and plated at the indicated cell number in RPMI supplemented with 10% FBS.
Transfections and Reporter Assays
A 3×-κB NF-κB-responsive luciferase reporter comprised of 3 tandem repeats from the MHC class I enhancer and a β-galactosidase reporter driven by the actin promoter (actin β-gal) were kindly provided by Drs. A. Baldwin (University of North Carolina) and M. Karin (University of California, San Francisco), respectively. Transfections were carried out using Lipofectamine 2000 (Invitrogen), according to manufacturer's protocol. Briefly, thyroid cancer cells (1.0 × 105) were transduced with either Ad-GFP (as an appropriate control) or Ad-mIκBα at the indicated MOI and seeded in 24-well plates 24 hours prior to transfection. DNA (0.8 μg) and Lipofectamine were diluted in Optimem at a Lipofectamine:DNA ratio of 2.5:1. After 4-6 hours, the media containing the complexes was removed from cells and replaced with fresh RPMI supplemented 10% FBS. Cells were harvested at 24 hours post-transfection in passive lysis buffer (PLB; Promega) and subjected to a single freeze-thaw cycle. The Luciferase Assay System (Promega) and Luminescent β-galactosidase Detection Kit II (Clontech) were used to assay luciferase and luminescent β-galactosidase activities, respectively. Luciferase relative light units (RLU) were normalized to luminescent β-galactosidase activity (RLU) to obtain a normalized measure of NF-κB transcriptional activity.
Western Blot Analysis
To prepare whole-cell extracts, cells were washed once with phosphate-buffered saline (PBS) and harvested in extraction buffer (EB; 1% Triton X-100, 10 mM Tris, pH 7.4, 5 mM EDTA, 50 mM NaCl, 50 mM NaF, 1 mM phenylmethylsulfonyl fluoride, and 2 mM Na3VO4 supplemented with 1× complete protease inhibitors (Roche Diagnostics). Cellular debris was then removed by centrifugation at 13,000 rpm for 10 minutes at 4°C. Nuclear and cytoplasmic extracts were prepared using the Nuclear Extract Kit (Active Motif), according to manufacturer's instructions. Extracts (40 μg) were resolved on 10% SDS-PAGE and transferred to Immobilon-P transfer membranes (Millipore). Membranes were probed with primary antibodies against PARP (rabbit polyclonal, AB16661, Millipore), cleaved PARP (mouse monoclonal, AB3565, Millipore), α-tubulin (mouse monoclonal, DM1A, Calbiochem), RelA (mouse monoclonal, F-6, Santa Cruz), IκBα (rabbit polyclonal, FL, Santa Cruz), ppSAPK/JNK (mouse monoclonal, #9255s, Thr-183/Tyr-185, Cell Signaling), SAPK/JNK (rabbit polyclonal, #9252, Cell Signaling), cyclin B1 (rabbit polyclonal, #4138, Cell Signaling), cyclin A (mouse monoclonal, #4656, Cell Signaling), and p21 (rabbit monoclonal, #2947, Cell Signaling) in blocking buffer (5% nonfat dry milk in 20 mM Tris, pH 7.4, 138 mM NaCl, 0.1% Tween (TBST)) overnight at 4°C. Membranes were washed with TBST and incubated with secondary goat anti-rabbit or goat anti-mouse horseradish peroxidase-conjugated antibody (GE Healthcare) for 3 h at room temperature. Immunoreactivity was visualized by enhanced chemiluminescence detection (Pierce). Blots were stripped and re-probed, where indicated, using Re-Blot Plus Mild (Millipore).
Automated Cell Counting Assays
For studies with pharmacologic inhibitors of NF-κB, thyroid cancer cells (1.5 × 104 - BCPAP, C643, SW1736, and 8505C; 7.5 × 103 - TPC1) were seeded in 6 cm plates. The following day, cells were treated with either vehicle (DMSO), IKK Inhibitor VII (1 μM), Bay 11-7082 (1 μM), or CDDO-Me (0.25 μM). Cells were replenished with fresh RPMI (10% FBS) supplemented with drug or vehicle after two days. After a total of five days of treatment, the media was collected, and adherent cells were washed with PBS and harvested by trypsinization. Cells were then combined with the collected media, centrifuged at 1,000 rpm for 5 minutes, and resuspended in 0.5 ml PBS. Viable cells were then counted using the Vi-CELL Coulter Counter (Beckman, Inc). For viral transduction studies, cells (1.5 × 104 - BCPAP, C643, SW1736, and 8505C; 7.5 × 103 - TPC1) were transduced as described above with either Ad-GFP or Ad-mIκBα at an MOI of 50 or 200 and then seeded in 6 cm plates. On the following day, the media was replaced with fresh RPMI (10% FBS). The media was again replaced with fresh RPMI (10% FBS) two days later. Five days post-transduction, media and cells were collected, and viable cell number was assessed as described above by ViCell counting.
Cell Cycle Analysis
8505C thyroid cancer cells (7.5 × 105) were transduced as described above with either Ad-GFP or Ad-mIκBα at an MOI of 25. Cells were then seeded in 10 cm dishes in RPMI (10% FBS). After 48 hours, adherent cells were harvested by trypsinization and washed with PBS. Cell pellets were resuspended in a saponin/propidium iodide solution (0.3% saponin, 25 μg/mL propidium iodide, 0.1 mM EDTA, and 10 μg/mL RNase A). Cells were incubated at 4°C for 8 hours, and cell cycle distribution was determined by flow cytometry using a Beckman Coulter FC500 at the University of Colorado Cancer Center Flow Cytometry Core. ModFit LT (Verity Software House) was used for cell cycle modeling and doublet discrimination.
Cell Viability Assays
Thyroid cancer cells were transduced with either Ad-GFP (as an appropriate control) or Ad-mIκBα at an MOI sufficient to achieve greater than 90% of NF-κB transcriptional activity, as determined by luciferase assay (BCPAP-200; SW1736-100; TPC1-50; C643-100). Cells (2,500/well for TPC1; 5,000/well for BCPAP, SW1736, and C643) were seeded in octuplicate into 96-well plates in RPMI supplemented with 10% FBS. Cells were treated the next day with medium containing 10 ng/ml TNFα (GenScript) (or vehicle) for three days, and cell viability was assayed after three days. Cell viability was measured per manufacturer's instructions using the CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay (Promega) with an MRX Microplate Reader (Dynatech Laboratories) and the Revelation software at an absorbance of 490 nm.
Assessment of Apoptosis
Apoptosis was assessed by Western blot analysis of cleaved PARP, as described above. For these studies, cells were serum-starved overnight prior to treatment. Cleaved PARP is the 89 kD cleavage product of poly (ADP-ribose) polymerase 1 (PARP1), which serves as a caspase substrate during the early stages of apoptosis .
Thyroid cancer cells were transduced as described above with either Ad-GFP or Ad-mIκBα at an MOI sufficient to achieve greater than 90% inhibition of NF-κB transcriptional activity, as determined by luciferase assay (BCPAP-200; SW1736-100; TPC1-50; C643-100). Twenty-four hours later, the media was replaced with fresh RPMI (0.1% FBS). After 6 hours, cells (1.0 × 105) were harvested and seeded in the upper chambers of Matrigel-coated transwell chambers (24-well, 8 μM pore size; BD Biosciences) in RPMI (0.1% FBS). Cell invasion was promoted by the presence of RPMI supplemented with 10% FBS in the lower chamber. After 24 hours, non-invading cells on the top chamber were removed by scraping with a cotton swab, and invading cells on the lower surface were fixed with methanol and stained with 3 μg/mL 4',6-diamidino-2-phenylindole (DAPI; Invitrogen). Cell invasion was assessed by counting DAPI-stained nuclei in five microscopic fields under 10× magnification using the Metamorph software (Molecular Devices) and Nikon microscope.
Thyroid cancer cells were transduced with either Ad-GFP (as an appropriate control) or Ad-mIκBα at an MOI sufficient to achieve greater than 90% of NF-κB transcriptional activity, as determined by luciferase assay (BCPAP-200; SW1736-100; TPC1-50; C643-100). Total RNA was isolated from the cells after 48 hours using the PerfectPure RNA Cultured Cell Kit (5 Prime) as per the manufacturer's protocol. The mRNA levels of MMP-2, -9, and -13 were measured by real-time quantitative reverse transcription-PCR using ABI PRISM 7700.
MMP-2; TaqMan Gene Expression Assay ID: HS00234422_m1.
MMP-9; Sense-CCCGGACCAAGGATACAGTTT, Antisense- GAATGATCTAAGCCCAGCGC, Probe-CCTCGTGGCGGCGCATGAG
MMP-13; Sense-TGGCATTGCTGACATCATGA; Antisense-GCCAGAGGGCCCATCAA, Probe-TGGAATTAAGGAGCATGGCGACTTCTACC
Amplification reactions and thermal cycling conditions were optimized for each primer-probe set and carried out by the University of Colorado Cancer Center QRT-PCR Core. A standard curve was generated using the fluorescent data from the 10-fold serial dilutions of control RNA. This was then used to calculate the transcripts levels of MMP-2, -9, and -13 in the RNA samples. Quantities of MMP-2, -9, and -13 in samples were normalized to the corresponding 18S rRNA (PE ABI, P/N 4308310).
Statistical significance between groups was determined using the two-tailed t-test (GraphPad Prism) [p < 0.05 (*); p < 0.01 (**); p < 0.001 (***)]
This work was supported by NCI CA100560 (BRH) and Mary Rossick Kern and Jerome H Kern Endowment (BRH). Cell cycle studies were performed by the University of Colorado Cancer Center Flow Cytometry Core supported by NIH grant P30 CA 046934. Quantitative RT-PCR studies were performed by the University of Colorado Cancer Center QRT-PCR Core.
- Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics. CA Cancer J Clin. 1997, 47: 5-27. 10.3322/canjclin.47.1.5View ArticlePubMedGoogle Scholar
- Haugen BR: Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol. 1999, 16: 34-41. 10.1002/(SICI)1098-2388(199901/02)16:1<34::AID-SSU7>3.0.CO;2-2View ArticlePubMedGoogle Scholar
- Nikiforov YE: Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol. 2008, 21 (Suppl 2): S37-S43. 10.1038/modpathol.2008.10PubMed CentralView ArticlePubMedGoogle Scholar
- Pfister DG, Fagin JA: Refractory thyroid cancer: a paradigm shift in treatment is not far off. J Clin Oncol. 2008, 26: 4701-4704. 10.1200/JCO.2008.17.3682View ArticlePubMedGoogle Scholar
- Sherman SI: Molecularly targeted therapies for thyroid cancers. Endocr Pract. 2009, 15: 605-611. 10.4158/EP09131.RARView ArticlePubMedGoogle Scholar
- Pacifico F, Leonardi A: NF-kappaB in solid tumors. Biochem Pharmacol. 2006, 72: 1142-1152. 10.1016/j.bcp.2006.07.032View ArticlePubMedGoogle Scholar
- Arsura M, Cavin LG: Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett. 2005, 229: 157-169. 10.1016/j.canlet.2005.07.008View ArticlePubMedGoogle Scholar
- Liu J, Suresh Kumar KG, Yu D, Molton SA, McMahon M, Herlyn M, Thomas-Tikhonenko A, Fuchs SY: Oncogenic BRAF regulates beta-Trcp expression and NF-kappaB activity in human melanoma cells. Oncogene. 2007, 26: 1954-1958. 10.1038/sj.onc.1209994PubMed CentralView ArticlePubMedGoogle Scholar
- Escarcega RO, Fuentes-Alexandro S, Garcia-Carrasco M, Gatica A, Zamora A: The transcription factor nuclear factor-kappa B and cancer. Clin Oncol (R Coll Radiol). 2007, 19: 154-161.View ArticleGoogle Scholar
- Brzoska K, Szumiel I: Signaling loops and linear pathways: NF-kappaB activation in response to genotoxic stress. Mutagenesis. 2009, 24: 1-8. 10.1093/mutage/gen056View ArticlePubMedGoogle Scholar
- Naugler WE, Karin M: NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev. 2008, 18: 19-26. 10.1016/j.gde.2008.01.020PubMed CentralView ArticlePubMedGoogle Scholar
- Karin M: Nuclear factor-kappaB in cancer development and progression. Nature. 2006, 441: 431-436. 10.1038/nature04870View ArticlePubMedGoogle Scholar
- Starenki DV, Namba H, Saenko VA, Ohtsuru A, Maeda S, Umezawa W, Yamashita S: Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin. Clin Cancer Res. 2004, 10: 6821-6829. 10.1158/1078-0432.CCR-04-0463View ArticlePubMedGoogle Scholar
- Meng Z, Mitsutake N, Nakashima M, Starenki D, Matsuse M, Takakura S, Namba H, Saenko V, Umezawa K, Ohtsuru A, Yamashita S: Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells. Endocrinology. 2008, 149: 5357-5365. 10.1210/en.2008-0279View ArticlePubMedGoogle Scholar
- Zhu W, Ou Y, Li Y, Xiao R, Shu M, Zhou Y, Xie J, He S, Qiu P, Yan G: A small-molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factor-kappa B pathway. Mol Pharmacol. 2009, 75: 812-819. 10.1124/mol.108.052605View ArticlePubMedGoogle Scholar
- Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J, Fanourakis G, Tseleni-Balafouta S, Ain KB, Mitsiades N: Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab. 2006, 91: 4013-4021. 10.1210/jc.2005-2472View ArticlePubMedGoogle Scholar
- Liu D, Xing M: Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways. Thyroid. 2008, 18: 853-864. 10.1089/thy.2007.0357PubMed CentralView ArticlePubMedGoogle Scholar
- Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR: Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab. 2008, 93: 4331-4341. 10.1210/jc.2008-1102PubMed CentralView ArticlePubMedGoogle Scholar
- Karin M, Yamamoto Y, Wang QM: The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov. 2004, 3: 17-26. 10.1038/nrd1279View ArticlePubMedGoogle Scholar
- Li B, Li YY, Tsao SW, Cheung AL: Targeting NF-kappaB signaling pathway suppresses tumor growth, angiogenesis, and metastasis of human esophageal cancer. Mol Cancer Ther. 2009, 8: 2635-2644. 10.1158/1535-7163.MCT-09-0162View ArticlePubMedGoogle Scholar
- Shishodia S, Sethi G, Konopleva M, Andreeff M, Aggarwal BB: A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin Cancer Res. 2006, 12: 1828-1838. 10.1158/1078-0432.CCR-05-2044View ArticlePubMedGoogle Scholar
- Deeb D, Gao X, Dulchavsky SA, Gautam SC: CDDO-me induces apoptosis and inhibits Akt, mTOR and NF-kappaB signaling proteins in prostate cancer cells. Anticancer Res. 2007, 27: 3035-3044.PubMedGoogle Scholar
- Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM: Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science. 1996, 274: 787-789. 10.1126/science.274.5288.787View ArticlePubMedGoogle Scholar
- Van Antwerp DJ, Verma IM: Signal-induced degradation of I(kappa)B(alpha): association with NF-kappaB and the PEST sequence in I(kappa)B(alpha) are not required. Mol Cell Biol. 1996, 16: 6037-6045.PubMed CentralView ArticlePubMedGoogle Scholar
- Wan YY, DeGregori J: The survival of antigen-stimulated T cells requires NFkappaB-mediated inhibition of p73 expression. Immunity. 2003, 18: 331-342. 10.1016/S1074-7613(03)00053-0View ArticlePubMedGoogle Scholar
- Luo JL, Kamata H, Karin M: IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. J Clin Invest. 2005, 115: 2625-2632. 10.1172/JCI26322PubMed CentralView ArticlePubMedGoogle Scholar
- Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9View ArticlePubMedGoogle Scholar
- Pacifico F, Mauro C, Barone C, Crescenzi E, Mellone S, Monaco M, Chiappetta G, Terrazzano G, Liguoro D, Vito P: Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomas. J Biol Chem. 2004, 279: 54610-54619. 10.1074/jbc.M403492200View ArticlePubMedGoogle Scholar
- Kaldis P, Aleem E: Cell cycle sibling rivalry: Cdc2 vs. Cdk2. Cell Cycle. 2005, 4: 1491-1494.View ArticlePubMedGoogle Scholar
- Flatt PM, Tang LJ, Scatena CD, Szak ST, Pietenpol JA: p53 regulation of G(2) checkpoint is retinoblastoma protein dependent. Mol Cell Biol. 2000, 20: 4210-4223. 10.1128/MCB.20.12.4210-4223.2000PubMed CentralView ArticlePubMedGoogle Scholar
- Xiao M, Inal CE, Parekh VI, Li XH, Whitnall MH: Role of NF-kappaB in hematopoietic niche function of osteoblasts after radiation injury. Exp Hematol. 2009, 37: 52-64. 10.1016/j.exphem.2008.09.001View ArticlePubMedGoogle Scholar
- Han SW, Roman J: Fibronectin induces cell proliferation and inhibits apoptosis in human bronchial epithelial cells: pro-oncogenic effects mediated by PI3-kinase and NF-kappa B. Oncogene. 2006, 25: 4341-4349. 10.1038/sj.onc.1209460View ArticlePubMedGoogle Scholar
- Raffoul JJ, Wang Y, Kucuk O, Forman JD, Sarkar FH, Hillman GG: Genistein inhibits radiation-induced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest. BMC Cancer. 2006, 6: 107- 10.1186/1471-2407-6-107PubMed CentralView ArticlePubMedGoogle Scholar
- Palona I, Namba H, Mitsutake N, Starenki D, Podtcheko A, Sedliarou I, Ohtsuru A, Saenko V, Nagayama Y, Umezawa K, Yamashita S: BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. Endocrinology. 2006, 147: 5699-5707. 10.1210/en.2006-0400View ArticlePubMedGoogle Scholar
- Papenfuss K, Cordier SM, Walczakya H: Death receptors as targets for anti-cancer therapy. J Cell Mol Med. 2008, 12: 2566-2585. 10.1111/j.1582-4934.2008.00514.xPubMed CentralView ArticlePubMedGoogle Scholar
- Papa S, Zazzeroni F, Pham CG, Bubici C, Franzoso G: Linking JNK signaling to NF-kappaB: a key to survival. J Cell Sci. 2004, 117: 5197-5208. 10.1242/jcs.01483View ArticlePubMedGoogle Scholar
- Tang F, Tang G, Xiang G, Dai Q, Rosner MR, Lin A: The absence of NF-kappaB-mediated inhibition of c-Jun N-terminal kinase activation contributes to tumor necrosis factor alpha-induced apoptosis. Mol Cell Biol. 2002, 22: 8571-8579. 10.1128/MCB.22.24.8571-8579.2002PubMed CentralView ArticlePubMedGoogle Scholar
- Bain J, McLauchlan H, Elliott M, Cohen P: The specificities of protein kinase inhibitors: an update. Biochem J. 2003, 371: 199-204. 10.1042/BJ20021535PubMed CentralView ArticlePubMedGoogle Scholar
- Noutomi T, Itoh M, Toyota H, Takada E, Mizuguchi J: Tumor necrosis factor-related apoptosis-inducing ligand induces apoptotic cell death through c-Jun NH2-terminal kinase activation in squamous cell carcinoma cells. Oncol Rep. 2009, 22: 1169-1172.PubMedGoogle Scholar
- Stamenkovic I: Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol. 2000, 10: 415-433. 10.1006/scbi.2000.0379View ArticlePubMedGoogle Scholar
- Min C, Eddy SF, Sherr DH, Sonenshein GE: NF-kappaB and epithelial to mesenchymal transition of cancer. J Cell Biochem. 2008, 104: 733-744. 10.1002/jcb.21695View ArticlePubMedGoogle Scholar
- Baldini E, Toller M, Graziano FM, Russo FP, Pepe M, Biordi L, Marchioni E, Curcio F, Ulisse S, Ambesi-Impiombato FS, D'Armiento M: Expression of matrix metalloproteinases and their specific inhibitors in normal and different human thyroid tumor cell lines. Thyroid. 2004, 14: 881-888. 10.1089/thy.2004.14.881View ArticlePubMedGoogle Scholar
- Duriez PJ, Shah GM: Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem Cell Biol. 1997, 75: 337-349. 10.1139/bcb-75-4-337View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.